Pneumococcal Infections Clinical Presentation
- Author: Dawn F Muench, MD; Chief Editor: Burke A Cunha, MD more...
History
After successful colonization, S pneumoniae can cause a wide variety of clinical symptoms. By direct extension from the nasopharynx, S pneumoniae infection can spread and then manifest as otitis media, sinusitis, tracheobronchitis, bronchitis, and pneumonia. By invasion and hematogenous spread, S pneumoniae infection can cause primary bacteremia, meningitis, osteomyelitis, pericarditis, endocarditis, myositis, septic arthritis, and peritonitis.
Factors that should prompt consideration of pneumococcal disease in patients with the above conditions include the following:
High-risk age groups
Children younger than 5 years, particularly aged 2 years or younger are at an increased risk of disease. In addition, absence of breastfeeding, exposure to cigarette smoke, daycare attendance, and lack of immunization with the pneumococcal conjugate vaccine further increase the risk of disease.
Adults older than 55-65 years are also at an increased risk of disease.
Immunodeficiencies
Conditions that cause immune deficits, including HIV infection, malignancy, diabetes mellitus, functional or actual absence of the spleen, humoral immunity defects, complement deficiencies, and neutrophil dysfunction, are associated with an increased risk of disease.
Conditions associated with decreased pulmonary clearance functions
These include asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), viral infections, and active/passive cigarette smoke exposure.
Presentation in the late fall to early spring
Pneumococcal infections peak in late fall to early spring in the Northern Hemisphere.
Physical
Clinical signs and symptoms and physical examination findings alone do not distinguish S pneumoniae disease from that caused by other pathogens.
Diseases Due to Direct Extension
Conjunctivitis
Bacterial conjunctivitis is more likely to be bilateral and purulent than viral conjunctivitis.
S pneumoniae is found in up to one third of patients with bacterial conjunctivitis; the rate of isolates that are not susceptible to penicillin is increasing.
Otitis media
S pneumoniae is the most commonly isolated bacterial pathogen from children and adults with otitis media.
Several early studies suggested or showed that S pneumoniae otitis media is usually accompanied by fever and pain and that the fever is higher than in otitis media caused by other common bacterial pathogens.[18]
Pneumococcal disease is less likely to resolve spontaneously.
Eustachian tube congestion caused by a preceding viral infection is common.
Increasing antibiotic resistance has led to decreased effectiveness of the antibiotics that were once used most commonly to treat otitis media.
S pneumoniae infection is the most common cause of mastoiditis, a complication of otitis media that was more common in the pre-antibiotic era; this complication is now more commonly associated with untreated or improperly treated cases of otitis media.
Sinusitis
As in otitis media, S pneumoniae is the most commonly isolated bacterial organism from patients with acute sinusitis.
Acute sinusitis manifestations may vary depending on the age of the patient and the developmental status of individual sinuses. In children younger than 5 years, infection is usually limited to the ethmoid and maxillary sinuses.
Acute sinusitis is usually preceded by a viral infection, leading to sinus mucosal swelling and ostia obstruction. This is followed by the development of a purulent discharge and cough.
Malodorous breath and worsening cough at night due to postnasal drip are often noted.
Acute exacerbations of chronic bronchitis (AECB)
Acute exacerbations of chronic bronchitis manifest as a change from baseline chronic symptoms. Symptoms include shortness of breath, increased production and/or purulence of sputum, increased sputum tenacity, and cough.
An estimated 80% of cases of acute exacerbations of chronic bronchitis are caused by infection, with about one half of those caused by aerobic bacteria, of which S pneumoniae is the most commonly isolated organism.
Symptoms such as sore throat, cold symptoms, and dyspnea may indicate a viral cause.[33]
Pneumonia
Classic pneumococcal pneumonia often develops in older children and adults. It may be preceded by a viral illness that is followed by an acute onset of high fever—often with rigors, productive cough, pleural pain, dyspnea, tachypnea, tachycardia, sweats, malaise, and fatigue.
Patients typically appear ill and may have an anxious appearance. On careful physical examination, rales can be heard in most patients. About half of all patients exhibit dullness to percussion, and splinting due to pain may be seen. Signs of effusion/empyema may be found on examination and include dullness to percussion at the bases. Diaphragmatic motion that is decreased from that expected in light of the patient's tachypnea.
In children (particularly school-aged and younger children), the potential manifestations of pneumonia are broad and often nonspecific. These may include nonspecific mild respiratory symptoms, with or without a cough on initial presentation; tachypnea, dyspnea, and splinting: high fever; abdominal pain; abdominal distention; anorexia; emesis (often suggesting a primary gastrointestinal disease); meningeal signs due to meningeal irritation with right upper lobe pneumonias; or chest pain due to pleural irritation.
In elderly patients with pneumococcal pneumonia, tachypnea may be the primary presenting sign. Temperature elevations may be mild or absent.
S pneumoniae is a common cause of bacterial CAP in HIV patients.
The most common complication of pneumococcal pneumonia is pleural effusion. Although up to 40% of patients with pneumococcal pneumonia may have pleural effusion, only an estimated 10% of these patients have enough fluid to aspirate, with only 2% of these patients meeting criteria for true empyema. S pneumoniae infection, along with Staphylococcusaureus infection, remains one of the most common causes of pediatric empyema.[18, 19, 34]
Invasive Disease
Meningitis
As a cause of meningitis, S pneumoniae usually invades the meninges via the bloodstream. Recent studies have shown that this is most likely due to pneumococcal adherence to up-regulated platelet-activating factor on vascular endothelial meningeal surfaces.
S pneumoniae can also directly invade the meninges after basilar skull fractures or other trauma that compromises the dura and is the most common cause of recurrent bacterial meningitis in these patients.
In countries with routine-vaccination policies, S pneumoniae infection is the most common cause of sporadic bacterial meningitis in both children and adults.
Most patients with pneumococcal meningitis present non-acutely after hours to days of developing signs and symptoms. Presenting signs and symptoms may be nonspecific and include fever, irritability, emesis, lethargy, anorexia, and malaise.
Neurologic signs and symptoms are usually prominent and may include mental-status changes, delirium, lethargy, nuchal rigidity with positive Brudzinski and Kernig signs, cranial nerve palsies, and other focal neurological deficits.
A bulging fontanelle and poor feeding may be seen infants.
Elderly patients may present with more indolent signs, including increasing lethargy, nonresponsiveness, or coma.
Twenty to 25% of patients with pneumococcal meningitis experience seizures.
Bacteremia may be found when blood cultures are obtained.
Prolonged or secondary fevers are not uncommon but do not usually affect outcomes.
Complications of pneumococcal meningitis include hearing loss, seizures, learning disabilities, mental difficulties, and cranial nerve palsies. In a study from Denmark, 240 patients who survived pneumococcal meningitis were examined using audiometry.[35] More than half (54%) had a hearing deficit, and 39% of those patients were not suspected of hearing loss at discharge from the hospital. Of the 240 patients, 7% had profound unilateral hearing loss, and another 7% had bilateral profound hearing loss. Significant risk factors for hearing loss included advanced age, the presence of comorbidity, and severity of meningitis. Audiometry should be performed on all patients who survive pneumococcal meningitis.
Pneumococcal meningitis carries a greater risk of death and significant neurological disabilities than does meningitis of other common bacterial causes (eg, Haemophilus influenzae type B [Hib] and Neisseria meningitidis).[18, 19, 34]
Bacteremia
Bacteremia is the most common manifestation of invasive pneumococcal disease.
Most cases are primary bacteremia and are found in children younger than 2 years. It is estimated that S pneumoniae infection has been the cause of 90% of occult bacteremia (bacteremia without a source) cases in these children since the widespread use of the Hib vaccine. The incidence of occult bacteremia has decreased since the institution of routine pneumococcal immunization in infants.[36, 37]
In adult patients, pneumococcal bacteremia is much more likely to be associated with another focal infection such as pneumonia, meningitis.
Signs, symptoms, and physical examination findings are usually nonspecific in patients with occult bacteremia due to pneumococcal infection.
In most patients, fever develops within 24 hours of positive culture findings. Higher temperatures are more often associated with the development of occult bacteremia.
A peripheral WBC count greater than 15,000 cells/μL is associated with the presence of occult bacteremia.
Bacteremia is less likely in patients with fever and signs or symptoms of focal infection (eg, otitis media).
Most cases of occult bacteremia spontaneously resolve.
Complications develop in an estimated 10% of patients with occult bacteremia and include meningitis, osteomyelitis, pneumonia, soft tissue and joint infections, and sepsis.
Patients with higher WBC counts and fever, those who have not undergone prior antibiotic therapy, and children younger than 20 months are at a higher risk for persistent bacteremia or the development of focal infection.[19, 18]
Joint and bone infections
S pneumoniae infection is an uncommon cause of osteomyelitis and septic arthritis, causing approximately 4% and 20% of cases in children, respectively.
Septic arthritis: Pneumococcal septic arthritis usually manifests as painful, swollen, and hot joints. The ankles and knees are most commonly involved, and one or more joints may be affected. Blood or synovial cultures usually grow S pneumoniae. Up to half of patients with pneumococcal septic arthritis have concomitant osteomyelitis.
Osteomyelitis: The femur and humerus are most often involved in cases of pneumococcal osteomyelitis in children; the vertebral bones are often involved in adult patients. Up to 20% of patients with pneumococcal osteomyelitis develop long-term sequelae, similar to rates of osteomyelitis sequelae caused by other organisms. One clinical study performed by the Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG) showed that more than 40% of patients with joint and bone pneumococcal infections had associated bacteremia.[38] Patients with prostheses or rheumatic fever are at increased risk for joint disease.
Soft tissue infections
Although uncommon, S pneumoniae infection can be a cause of mild-to-serious soft tissue infections, including cellulitis, myositis, periorbital cellulitis, and abscess, particularly in some compromised hosts (eg, those with SLE). Most patients have WBC counts greater than 15,000 cells/μL and elevated temperatures. Physical findings are related to the site of infection and usually include redness, warmth, and tenderness of the involved area. Movement may be limited by pain and/or swelling. The incidence of soft tissue infections is increased in persons with HIV infection or underlying connective tissue disease; however, most affected individuals are otherwise healthy and respond well to antibiotic therapy.[18]
Peritonitis
Overall, primary peritonitis (peritonitis caused by the spread of organisms via blood or lymph to the peritoneal cavity) is rare, accounting for less than 20% of peritonitis cases.
S pneumoniae is the most commonly isolated organism in patients with primary peritonitis.
Primary peritonitis in children is usually associated with underlying conditions such as nephrotic syndrome or other immunocompromising diseases.
In adults, primary peritonitis is usually associated with cirrhosis.
Females with severe pelvic inflammatory disease due to S pneumoniae infection may develop peritonitis. In such cases, organisms may gain access to the peritoneum via the fallopian tubes from the female genital tract. This is the only invasive disease caused by S pneumoniae infection that is more common in females.
Other persons at risk for peritonitis include persons with gastrointestinal injury, ulcers, or malignancy.
Presenting symptoms of peritonitis include abdominal pain, anorexia, emesis, diarrhea, and fever; children with right lower quadrant abdominal pain are often initially investigated for appendicitis.
Cardiac infections
In the antibiotic era, pneumococcal cardiac infections are rare.
Endocarditis: Involvement of native aortic and mitral valves are most common; infection can lead to valve destruction, heart failure, and embolization. Presenting signs and symptoms are typical of those seen in other causes of endocarditis and include fever, new or changing murmurs, muscle and/or joint pains, sweating, fatigue, anorexia, and skin findings. In alcoholics, may be part of the triad of endocarditis, pneumonia, and meningitis.
Pericarditis: Prior to the widespread use of antibiotics, S pneumoniae infection was the most common cause of purulent pericarditis in children; now, infection in childhood is extremely rare, and nearly all cases of pneumococcal pericarditis occur in adults. Symptoms, signs, and examination findings may include chest and/or pleuritic pain; radiating pain to the neck, abdomen, shoulder, or back; orthopnea; dry cough; extremity swelling; anxiety; fatigue; fever; pericardial rub; and muffled heart sounds.
Causes
S pneumoniae is an encapsulated, gram-positive, catalase-negative cocci that grows as a facultative anaerobe. These organisms often appear on Gram stain as lancet-shaped diplococci that grow in chains (see image below). On blood and chocolate agar plates, a green zone (alpha-hemolysis; due to the breakdown of hemoglobin by pneumolysin) surrounds the colonies. Other identifying properties include sensitivity to optochin (which distinguishes it from other alpha-hemolytic streptococci) and bile solubility.
Sputum Gram stain from a patient with a pneumococcal pneumonia. Note the numerous polymorphonuclear neutrophils and gram-positive, lancet-shaped diplococci. Courtesy of C. Sinave, MD, personal collection. Predisposing conditions to pneumococcal infection are broad and often overlap; they include the following:
- Exposure
- Cigarette smoke
- Alcohol
- Glucocorticosteroids
- Cold
- Stress
- Prior respiratory infections (including influenza)
- Daycare attendance
- Homeless shelters
- Military training
- Prisons
- Malnutrition
- Lack of exposure to breastmilk
- Defects in clearance of pneumococci from the blood
- Congenital asplenia
- Splenectomy
- Decreased splenic function due to autosplenectomy due to sickle cell disease
- Defects in clearance from sinopulmonary tissue or inflammatory conditions
- Asthma
- COPD
- Cigarette smoking
- Influenza and other respiratory viral infections
- Defective antibody formation
- Primary
- Congenital agammaglobulinemia
- Common variable hypogammaglobulinemia
- Selective immunoglobulin G (IgG) subclass deficiency
- Secondary
- Lymphoma
- Chronic lymphocytic leukemia
- Multiple myeloma
- HIV infection
- Primary
- Defective complement (primary or secondary): Absent or decreased amounts of C1, C2, C3, or C4
- Abnormalities in polymorphonuclear leukocytes
- Decreased levels associated with cyclic neutropenia, drug-induced neutropenia, or aplastic anemia
- Decreased function caused by conditions such as alcoholism, cirrhosis, diabetes mellitus, renal insufficiency, and steroid therapy
- Other
- Age (children < 2 y and elderly persons)
- Fatigue
- Chronic disease
- Hospitalization[19]
Active Bacterial Core Surveillance (ABCs) Report; Emerging Infections Program Network; Streptococcus pneumoniae [database online]. CDC website: CDC; September 2009. Updated 2009.
Committee on Infectious Diseases; American Academy of Pediatrics. Pneumococcal Infections. In: Pickering LK, Baker CJ, Long SS, McMillan JA. Red Book 2009 Report of the Committee on Infectious Diseases. 28th. American Academy of Pediatrics; 2009:525-335.
Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. Feb 15 2008;57(6):144-8. [Medline]. [Full Text].
Hsu KK, Shea KM, Stevenson AE, Pelton SI,. Changing Serotypes Causing Childhood Invasive Pneumococcal Disease: Massachusetts, 2001-2007. Pediatr Infect Dis J. Nov 21 2009;[Medline].
Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. Apr 25 2007;297(16):1784-92. [Medline].
Ongkasuwan J, Valdez TA, Hulten KG, Mason EO Jr, Kaplan SL. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics. Jul 2008;122(1):34-9. [Medline]. [Full Text].
Eiland LS. Increasing Prevalence of Pneumococcal Serotype 19A Among US Children. Journal of Pharmacy Practice. 2008;21(5):356-62.
Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. Apr 25 2007;297(16):1784-92. [Medline].
McNeil JC, Hulten KG, Mason EO Jr, Kaplan SL. Serotype 19A is the Most Common Streptococcus pneumoniae Isolate in Children With Chronic Sinusitis. Pediatr Infect Dis J. Sep 2009;28(9):766-8. [Medline].
Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 201(1);2010 Jan 1:32-41. [Medline].
Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep. Mar 12 2010;59(9):253-7. [Medline]. [Full Text].
Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. Mar 12 2010;59(9):258-61. [Medline]. [Full Text].
McEllistrem MC, Adams JM, Patel K, Mendelsohn AB, Kaplan SL, Bradley JS, et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. Jun 15 2005;40(12):1738-44. [Medline]. [Full Text].
Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics. Apr 2007;119(4):707-15. [Medline].
Poehling KA, Lafleur BJ, Szilagyi PG, Edwards KM, Mitchel E, Barth R, et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics. Sep 2004;114(3):755-61. [Medline].
Mitchell AM, Mitchell TJ. Streptococcus pneumoniae: virulence factors and variation. Clin Microbiol Infect. May 2010;16(5):411-8. [Medline].
Ghaffar F, Friedland IR, McCracken GH Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J. Jul 1999;18(7):638-46. [Medline].
Dagan R, Greenberg D, Jacobs MR. Pneumococcal Infections. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL. Textbook of Pediatric Infectious Diseases. 1. 5th. Philadelphia, Pennsylvania: Saunders (Elsevier Science); 2004:1204-1258/90.
Musher DM. Streptococcus pneumoniae. In: Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 2. 6th. Philadelphia, Pennsylvania: Elsevier, Churchill Livingstone; 2005:197.
Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. May 2010;16(3):217-25. [Medline].
CDC. Streptococcus pneumoniae Disease. CDC.gov. Available at http://www.cdc.gov/ncidod/dbmd/diseaseinfo/streppneum_t.htm. Accessed December 5, 2009.
CDC. 2009 H1N1 Pandemic Update: Pneumococcal Vaccination Recommended to Help Prevent Secondary Infections. CDC website: CDC; November 16, 2009. [Full Text].
Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep. Oct 2 2009;58(38):1071-4. [Medline]. [Full Text].
WHO Initiative for Vaccine Research Division. Acute Respiratory Infections, Streptococcus pneumoniae. World Health Organization (WHO). Available at http://www.who.int/vaccine_research/diseases/ari/en/index5.html#vaccine.
National Center for Immunization and Respiratory Diseases / Division of Bacterial Diseases. ABCs Report: Streptococcus pneumoniae, PROVISIONAL 2008Active Bacterial Core Surveillance (ABCs): Emerging Infections Program Network. CDC.gov: CDC; 1 September 2009. [Full Text].
Goetghebuer T, West TE, Wermenbol V, Cadbury AL, Milligan P, Lloyd-Evans N, et al. Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia. Trop Med Int Health. Mar 2000;5(3):207-13. [Medline]. [Full Text].
Eskola J, Black S, Shinefield H. Pneumococcal conjugate vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia, PA: Elsevier Inc; 2004:23.
Scott JA. The preventable burden of pneumococcal disease in the developing world. Vaccine. Mar 22 2007;25(13):2398-405. [Medline].
Fedson DS, Scott JA. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine. Jul 30 1999;17 Suppl 1:S11-8. [Medline].
World Health Organization. Weekly Epidemiological Record. March/2007. [Full Text].
WHO.INT; Immunization, Vaccines and Biologicals Division. Pneumococcal Vaccines. WHO.INT. Available at http://www.who.int/vaccines/en/pneumococcus.shtml. Accessed April 2003.
Rudan I, Campbell H. The deadly toll of S pneumoniae and H influenzae type b. Lancet. Sep 12 2009;374(9693):854-6. [Medline].
[Guideline] Brunton S, Carmichael BP, Colgan R, Feeney AS, Fendrick AM, Quintiliani R, et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am J Manag Care. Oct 2004;10(10):689-96. [Medline].
Peter G, Klein JO. Streptococcus pneumoniae. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practices of Pediatric Infectious Diseases. 2nd ed. Philadelphia, PA: Churchill Livingstone (Elsevier); 2002:739-746/131.
Worsoe L, Caye-Thomasen P, Brandt CT, Thomsen J, Ostergaard C. Factors associated with the occurrence of hearing loss after pneumococcal meningitis. Clin Infect Dis. Oct 15 2010;51(8):917-24. [Medline].
Waddle E, Jhaveri R. Outcomes of febrile children without localising signs after pneumococcal conjugate vaccine. Arch Dis Child. Feb 2009;94(2):144-7. [Medline]. [Full Text].
Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a Children's Hospital Emergency Department and Urgent Care Center. Arch Pediatr Adolesc Med. Jul 2004;158(7):671-5. [Medline]. [Full Text].
Bradley JS, Kaplan SL, Tan TQ, Barson WJ, Arditi M, Schutze GE, et al. Pediatric pneumococcal bone and joint infections. The Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG). Pediatrics. Dec 1998;102(6):1376-82. [Medline].
American Academy of Pediatrics/American Academy of Family Physicians. Clinical Practice Guideline: Diagnosis and Management of Acute Otitis Media. www.aafp.org. Available at http://www.aafp.org/online/etc/medialib/aafp_org/documents/clinical/clin_recs/otitismedia.Par.0001.File.dat/final_aom.pdf. Accessed March 2004.
Anevlavis S, Petroglou N, Tzavaras A, Maltezos E, Pneumatikos I, Froudarakis M, et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect. Aug 2009;59(2):83-9. [Medline].
Casado Flores J, Nieto Moro M, Berrón S, Jiménez R, Casal J. Usefulness of pneumococcal antigen detection in pleural effusion for the rapid diagnosis of infection by Streptococcus pneumoniae. Eur J Pediatr. May 2010;169(5):581-4. [Medline].
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 18th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
Centers for Disease Control and Prevention. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae- United States, 2006-2007. MMWR Morb Mortal Wkly Rep.: CDC; 2008. [Full Text].
Cunha BA. Pneumonia Essentials. 2nd ed. Sudbury, MA: Jones & Bartlett, Publishers; 2010.
Fung HB, Monteagudo-Chu MO. Community-acquired pneumonia in the elderly. Am J Geriatr Pharmacother. Feb 2010;8(1):47-62. [Medline].
Johnstone J. Review: pneumococcal vaccination is not effective for preventing pneumonia, bacteraemia, bronchitis, or mortality. Evid Based Med. Aug 2009;14(4):109. [Medline].
Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis. Jul 1 2010;51(1):15-22. [Medline].
Luján M, Gallego M, Belmonte Y, Fontanals D, Vallès J, Lisboa T, et al. Influence of pneumococcal serotype group on outcome in adults with bacteremic pneumonia. Eur Respir J. Feb 11 2010;[Medline].
Donowitz GR, Mandell GL. Acute pneumonia. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000:717-43.
Madeddu G, Fois AG, Pirina P, Mura MS. Pneumococcal pneumonia: clinical features, diagnosis and management in HIV-infected and HIV noninfected patients. Curr Opin Pulm Med. May 2009;15(3):236-42. [Medline].
Austrian R. Pneumococcal pneumonia. Diagnostic, epidemiologic, therapeutic and prophylactic considerations. 1986. Chest. Nov 2009;136(5 Suppl):e30. [Medline].
Clifford V, Tebruegge M, Vandeleur M, Curtis N. Question 3: can pneumonia caused by penicillin-resistant Streptococcus pneumoniae be treated with penicillin?. Arch Dis Child. Jan 2010;95(1):73-7. [Medline].
Cunha BA. Clinical relevance of penicillin-resistant Streptococcus pneumoniae. Semin Respir Infect. Sep 2002;17(3):204-14. [Medline].
Garnacho-Montero J, García-Cabrera E, Diaz-Martín A, Lepe-Jiménez JA, Iraurgi-Arcarazo P, Jiménez-Alvarez R, et al. Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment. Scand J Infect Dis. Mar 2010;42(3):185-92. [Medline].
van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. Oct 31 2009;374(9700):1543-56. [Medline].
van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis. Mar 2004;4(3):139-43. [Medline].
Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis. Apr 15 2003;36(8):963-70. [Medline].
Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. Dec 28 2000;343(26):1917-24. [Medline].
Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. Jun 2004;48(6):2101-7. [Medline].
Cunha BA. Effective antibiotic-resistance control strategies. Lancet. Apr 28 2001;357(9265):1307-8. [Medline].
Shea KW, Cunha BA, Ueno Y, Abumustafa F, Qadri SM. Doxycycline activity against Streptococcus pneumoniae. Chest. Dec 1995;108(6):1775-6. [Medline].
[Guideline] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. Mar 1 2007;44 Suppl 2:S27-72. [Medline].
Hawser SP. Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP). J Infect. Apr 2010;60(4):306-8. [Medline].
[Guideline] American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics. Jul 2010;126(1):186-90. [Medline].
[Guideline] Advisory Committee on Immunization Practices (ACIP). Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. Oct 6 2000;49:1-35. [Medline]. [Full Text].
[Guideline] Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep. Apr 4 2008;57(13):343-4. [Medline]. [Full Text].
Domínguez A, Izquierdo C, Salleras L, Ruiz L, Sousa D, Bayas JM, et al. Effectiveness of the pneumococcal polysaccharide vaccine in Preventing Pneumonia in the elderly. Eur Respir J. Jan 14 2010;[Medline].
Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics. Sep 2006;118(3):865-73. [Medline].
Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. Sep 3 2010;59(34):1102-6. [Medline].
Rinta-Kokko H, Dagan R, Givon-Lavi N, Auranen K. Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine. Jun 12 2009;27(29):3831-7. [Medline].
Hung IF, Leung AY, Chu DW, Leung D, Cheung T, Chan CK. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. Nov 1 2010;51(9):1007-16. [Medline].
Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. Dec 2001;20(12):1105-7. [Medline].
Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, Tan TQ, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. Mar 2004;113(3 Pt 1):443-9. [Medline].
Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med. Jul 11 2005;165(13):1533-40. [Medline].
| Age at Examination (mo) | Immunization History | Recommended Regimena |
| 2-6 | 0 doses | 3 doses, 2 mo apart; fourth dose at age 12-15 mo |
| 1 dose | 2 doses, 2 mo apart; fourth dose at age 12-15 mo | |
| 2 doses | 1 dose, 2 mo after the most recent dose; fourth dose at age 12-15 mo | |
| 7-11 | 0 doses | 2 doses, 2 mo apart; third dose at age 12 mo |
| 1 or 2 doses before age 7 mo | 1 dose at age 7-11 mo, with another dose at age 12-15 mo (≥2 mo later) | |
| 12-23 | 0 doses | 2 doses, ≥2 mo apart |
| 1 dose at < 12 mo | 2 doses, ≥2 mo apart | |
| 1 dose at ≥12 mo | 1 dose, ≥2 mo after the most recent dose | |
| 2 or 3 doses at < 12 mo | 1 dose, ≥2 mo after the most recent dose | |
| 24-71[66] | ||
| Healthy children (24-59mo) | Any incomplete schedule | 1 dose, ≥2 mo after the most recent doseb |
| Children at high riskc (24-71 mo) | Any incomplete schedule of < 3 doses | 2 doses, one ≥2 mo after the most recent dose and another dose ≥2 mo later |
| Any incomplete schedule of 3 doses | 1 dose, ≥2 mo after the most recent dose | |
| a In children immunized before age 12 mo, the minimum interval between doses is 4 weeks. Doses administered at age 12 months or later should be administered at least 8 weeks apart. b Providers should administer a single dose to all healthy children aged 24-59 mo with any incomplete schedule. c Children with sickle cell disease, asplenia, chronic heart or lung disease, diabetes mellitus, CSF leak, cochlear implant, HIV infection, or another immunocompromising condition. PPV23 is also indicated (see below). | ||

